Maziar Mike Doustdar has been appointed president and chief executive officer of Novo Nordisk, effective August 7, 2025, taking the helm of the world's largest diabetes and obesity drugmaker at a critical juncture when it faces pricing pressures, manufacturing bottlenecks, and intensifying competition from Eli Lilly. The appointment was announced July 29 following a comprehensive search that evaluated both internal and external candidates. Doustdar, 55, succeeds Lars Fruergaard Jørgensen, who led the company for eight years as it scaled Ozempic and Wegovy into blockbusters that transformed the global diabetes and weight-loss markets.
Doustdar's appointment comes at a moment when Novo Nordisk's market dominance is slipping. The company has seen its share price tumble, downgraded guidance twice, and faced supply constraints that have allowed compounded versions of semaglutide to capture roughly 1.5 million US patients seeking lower-cost alternatives. Chair Helge Lund said Doustdar has "the unanimous support of the Board" and described him as "an exceptional leader" with "strong commercial execution" abilities. The Novo Nordisk Foundation, which holds controlling voting rights, explicitly endorsed the decision. Doustdar's promotion from executive vice president of International Operations marks a deliberate choice to keep the succession internal, with industry observers noting that his three decades at the company provided institutional knowledge that would accelerate decision-making compared to an external hire.
Doustdar joined Novo Nordisk in 1992 as an office clerk in Vienna while still studying at Webster University, where he earned a bachelor's degree in international business in 1994. His career trajectory has been marked by deep operational experience in emerging markets across Europe, the Middle East, and Asia-Pacific. In 2007, he became general manager of the Near East business, overseeing operations across seven challenging markets including Afghanistan, Iran, Iraq, and Syria from an Istanbul base. By 2013, he was promoted to senior vice president of Emerging Markets, overseeing 150 countries. In 2015, Doustdar was elevated to executive vice president of International Operations, a position he held when the board selected him for the top job. Under his stewardship, International Operations more than doubled sales to approximately 112 billion DKK (roughly $15 billion) by 2024, serving 35 million patients with a workforce of nearly 20,000. He holds a degree in international business from Webster University and completed an executive education programme at Harvard Business School in 2012. Born in Iran and raised in the United States before settling in Austria, Doustdar is fluent in English, Farsi, and German. The appointment makes him Novo Nordisk's first non-Danish chief executive since the company's 1989 merger.
Novo Nordisk, headquartered in Bagsværd, Denmark, is among the world's largest pharmaceutical companies by market capitalization, employing approximately 78,400 people across 80 offices globally. The company's diabetes and obesity segment generated 289.5 billion DKK in revenues in 2025, representing 93.6 percent of total sales. Ozempic and Wegovy, both containing the active ingredient semaglutide, have driven unprecedented growth but have also made the company heavily dependent on a narrow portfolio. Founded in 1923, Novo Nordisk pioneered the GLP-1 space and established a commanding position in obesity treatment. Yet in 2025, Eli Lilly surpassed Novo as the market leader in cardiometabolic revenue, driven by dual-action therapies Mounjaro and Zepbound, which demonstrated superior weight loss efficacy in clinical trials.
Doustdar's first months as CEO have been marked by decisive action reflecting his stated priority of operational speed. In September 2025, just weeks after taking office, he announced a sweeping restructuring eliminating approximately 9,000 positions, or 11 percent of the global workforce, with 5,000 reductions concentrated in Denmark. The move generated one-time costs of 8 billion DKK but promises 8 billion DKK in annualized savings by year-end 2026. Doustdar framed the restructuring as necessary to simplify decision-making and redirect resources toward core diabetes and obesity therapies. In January 2026, Novo launched an oral formulation of Wegovy at a $149 monthly starting price, which Doustdar characterized as achieving "very encouraging" early uptake, with roughly 50,000 weekly prescriptions within months. His strategy appears calibrated to address the pricing sensitivity that has allowed compounders to capture market share while competing against Eli Lilly's higher-efficacy tirzepatide compounds. However, analysts note the company still faces headwinds from patent expiration timelines, manufacturing constraints, and Lilly's anticipated launch of an oral GLP-1 candidate expected to deliver superior weight loss compared to Novo's pill. Doustdar acknowledged these challenges directly in early 2026 guidance, stating the company would face "pricing headwinds in an increasingly competitive market." The appointment reflects Novo Nordisk's judgment that restoring market leadership and share price performance requires a CEO who combines deep operational familiarity with the urgency to execute rapid change amid disruption in the obesity market.
